ArticleCancer reports (Hoboken, N.J.)2026
Epidemiology and Prognosis of Patients With Osteosarcoma at Different Primary Sites: A SEER Population-Based Study.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiology and Prognosis of Patients With Osteosarcoma at Different Primary Sites: A SEER Population-Based Study.Cancer reports (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOsteosarcoma is a primary bone malignancy with a known bimodal age distribution. However, epidemiological patterns based on precise primary anatomical sites are not well characterized. This population-based study analyzed the Surveillance, Epidemiology, and End Results (SEER) database to compare the incidence and clinical features of central-site versus peripheral-site osteosarcoma across different age groups.
aimsThis study aimed to compare the incidence characteristics of peripheral and central-site osteosarcoma (OS) and to explore the impact of different primary sites on the prognosis of patients with OS.
methodsPatients diagnosed with OS (1975-2019) were selected from the SEER databases. The different primary sites, diagnosis time, and incidence of OS were described statistically. A 1:1 propensity score matching (PSM) was used to adjust for clinical characteristics and treatment. Kaplan-Meier curves were used to compare overall survival and CSS of peripheral and central-site OS before and after matching. Univariate and multivariate Cox models were used to investigate prognostic factors for CSS in both groups.
resultsA total of 3129 patients were included (899/28.73% central-site OS, 2166/69.22% peripheral-site OS, 64/2.05% other-site OS). After PSM, central-site OS had lower overall survival and CSS than peripheral-site OS (5-year overall survival, 0.415 vs. 0.468; 5-year CSS, 0.454 vs. 0.555). Multivariate analysis revealed that age (p = 0.010), primary site (p = 0.039), historical SEER stage (regional, p = 0.012; distant, p < 0.001), histologic grade (grade III, p = 0.014; grade IV, p = 0.009), surgery (p < 0.001), and radiotherapy (p = 0.005) were significant factors for CSS. Subgroup analyses adjusting for these factors showed better CSS in peripheral-site OS patients.
conclusionsThe incidence of central-site OS is lower than that of peripheral-site OS, while the prognosis of patients with peripheral-site OS is more favorable than that of patients with central-site OS. Surgical intervention is a cornerstone in the management of OS and is effective for both central-site and peripheral-site OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.